Overview

Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients

Status:
Recruiting

Trial end date:
2024-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of decitabine combined with HAAG regimen in the treatment of newly diagnosed patients with ETP-ALL/LBL, T/M-MPAL and ALL/LBL with myeloid or stem cell markers.

Phase:

Phase 3

Details

Lead Sponsor:

The First Affiliated Hospital of Soochow University

Collaborators:

Changzhou No.2 People's Hospital
Henan Cancer Hospital
Shandong Provincial Hospital
Shenzhen People's Hospital
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
The First Affiliated Hospital of Anhui Medical University
The Second People's Hospital of Huai'an

Treatments:

Decitabine